Currently, standard treatment for endometrial cancer is chemotherapy alone. But adding pembrolizumab to a chemotherapy regimen improved progression-free survival in patients with advanced or recurrent endometrial cancer, according to results from a phase 3 trial that included 816 patients.
Source: JAMA Online First